Lonidamine
Lonidamine is an orally administered small molecule hexokinase inactivator. (In Vitro) :Lonidamine (100 μM, 24 h) inhibits TGF-β-stimulated lactate production and oxygen consumption rate in AKR-2B and TIG-1 cells.Lonidamine (100 μM, 24/48 h) inhibits H2030BrM3 and A549 cell proliferation.Lonidamine (100-200 μM, 24 h) inhibits H2030BrM3 and A549 cell invasion.Lonidamine (100-1000 μM, 24 h) inhibits mitochondrial complex I and II activities.Lonidamine (200 μM, 24 h) increases ROS generation in H2030BrM3 lung cancer cells. (In Vivo) :Lonidamine (oral administration, 10-100 mg/kg/day, d10 to d20) improves lung function by inhibiting hexokinase 2 (HK2) activity in BLM-induced pulmonary fibrosis murine model.
Product Specifications
CAS Number
50264-69-2
Product Name Alternative
AF 1890 | DICA | Diclondazolic Acid
Field of Research
Pharmacology & Drug Discovery
Purity
>98% (HPLC)
Solubility
DMSO: 64 mg/mL (199.27 mM)
Smiles
O=C (C1=NN (CC2=CC=C (Cl) C=C2Cl) C3=C1C=CC=C3) O
Molecular Formula
C15H10Cl2N2O2
Molecular Weight
321.17
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
1- (2,4-dichlorobenzyl) -1H-indazole-3-carboxylic acid
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
DENND5B, CT (DENND5B, DENN domain-containing protein 5B, Rab6IP1-like protein) (APC) discontinued
FGF8 (Fibroblast Growth Factor 8 (androgen-Induced), AIGF, HBGF-8, MGC149376) (MaxLight 490)
